Dr. Lal PathLabs Limited (BOM:539524)
2,006.55
+44.40 (2.26%)
At close: Nov 20, 2026
Dr. Lal PathLabs Stock Forecast
Stock Price Forecast
According to 26 analysts polled by S&P Global, Dr. Lal PathLabs stock has a consensus rating of "Buy" and an average price target of ₹2,213. The average 1-year stock price forecast is 10.30% higher than the current stock price, while the lowest is ₹1,180 (-41.19%) and the highest is ₹2,675 (+33.31%).
Price Target: ₹2,213 (+10.30%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Dr. Lal PathLabs stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 16 | 16 | 17 | 17 | 15 |
| Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Hold | 1 | 3 | 3 | 3 | 3 | 4 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 2 | 2 | 3 |
| Total | 26 | 26 | 26 | 26 | 26 | 26 |
Financial Forecast
Revenue This Year
32.69B
from 27.63B
Increased by 18.31%
Revenue Next Year
37.40B
from 32.69B
Increased by 14.40%
EPS This Year
39.43
from 30.40
Increased by 29.70%
EPS Next Year
45.66
from 39.43
Increased by 15.81%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.